Navigation Links
Neurocrine Biosciences Amends Corporate Headquarters Lease
Date:10/1/2009

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has entered into an amendment to its facility lease agreement. The amendment eliminates approximately 70,000 square feet of leased space.

"We worked with our landlord in a collaborative manner to reduce our leasing obligation and to allow them to directly market the property, while at the same time minimizing the cash flow impact to Neurocrine," said Timothy P. Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences. "This is a significant first step in reducing our fixed real estate cost structure, reducing our overall obligation by approximately $27 million."

Under the terms of the lease amendment, Neurocrine will vacate the front building of the two building campus and will make an immediate payment of $4 million to the landlord as an initial release fee. Additionally, the Company has agreed to make certain rent payments and rent differential payments with respect to the released space.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com

SOURCE Neurocrine Biosciences, Inc.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences Secures Committed Equity Financing Facility
3. Neurocrine Biosciences Reports Second Quarter 2009 Results
4. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
6. Neurocrine Biosciences to Present at the 8th Annual Needham Life Sciences Conference
7. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
8. Neurocrine Biosciences Reports First Quarter 2009 Results
9. Neurocrine Announces Work Force Restructuring
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... Edward Lanphier , Sangamo,s president and chief executive officer, ... ZFP Therapeutic ® development programs and an overview ... on Thursday, February 11, 2016, at the Leerink Partners ... is being held in New York ...
(Date:2/4/2016)... , Feb. 4, 2016 Beike Biotechnology, the ... medical institutions attended a ceremony in late 2015 to ... cell therapy in 2016. --> ... Translation Platform for Personalized Cell Therapy" was hosted by ... Production Center, both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... --> --> ... pleased to provide the following update on recent corporate developments. ... last 3 months we have significantly increased our cash position ... As a result, we have positioned ourselves to execute on ... and expect that development to continue on schedule. ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
Breaking Biology News(10 mins):